Compare Amgen, Inc. (AMGN) vs Bath & Body Works Inc (BBWI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Bath & Body Works Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Bath & Body Works Inc trades at $20.33 (market cap $4.10B). The key difference: Amgen, Inc. is far larger — about 47.8× Bath & Body Works Inc's market cap, and Bath & Body Works Inc pays the higher dividend (3.94%). Which is the better fit depends on your goals.
| AMGN | BBWI | |
|---|---|---|
Market Cap | $196.12B | $4.10B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $33.11 |
52-Week Low | $271.18 | $14.85 |
Enterprise Value | $241.41B | $7.99B |
Dividend Yield | 2.77% | 3.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
BBWI trades at $20.33, up 2.01% today, with a bearish technical signal but neutral oscillators. The stock shows strong profitability with a net margin of 10.03% and attractive valuation ratios, including a P/E of 5.78. Recent earnings beat expectations in Q1 2026, and the company's partnership with Ulta Beauty aims to expand reach. Cash flow trends indicate improving net cash flow by 2026, though the balance sheet carries significant debt.
The outlook is mixed: analyst consensus is a Buy with a $22.00 price target, suggesting upside, but risks include declining revenue over five years and high leverage. The Ulta partnership and cost-saving initiatives offer growth potential, yet competitive pressures and macroeconomic headwinds pose challenges for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Bath & Body Works Inc
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with less than 5% of sales from international markets in fiscal 2021. For fiscal 2021, 72% of sales stemmed from the brick-and-mortar network (which is composed of more than 1,700 retail stores), up from 65% in 2020, as consumer shopping patterns began to return to normal. Future growth is expected from store reformatting, digital and international channels, as well as new category expansion.
Read more on BBWI →
